| Market Capitalization (Millions $) |
283 |
| Shares
Outstanding (Millions) |
40 |
| Employees |
157 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-134 |
| Cash Flow (TTM) (Millions $) |
-109 |
| Capital Exp. (TTM) (Millions $) |
2 |
Iteos Therapeutics Inc
Iteos Therapeutics Inc.
is a clinical-stage biotechnology company that was founded in 2011 in Belgium.
The company is focused on developing immuno-oncology therapies that can activate the patient's immune system to fight cancer.
They aim to provide cancer patients with long-lasting and meaningful clinical benefit.
Iteos has developed a proprietary platform technology that identifies novel targets for cancer immunotherapy.
Their lead product candidate is an anti-TIGIT antibody, which is currently in Phase 1/2 clinical trials for a range of solid tumor types.
The company also has several other drug candidates in its pipeline, including an anti-CD39 antibody and a STING agonist.
The company has extensive collaborations with academic institutions and pharmaceutical companies, including GlaxoSmithKline, Merck, and Sanofi.
These collaborations enable them to access expertise and resources that enhance their research capabilities.
Iteos has a global presence and operates from its headquarters in Cambridge, Massachusetts, and also has European offices in Gosselies, Belgium.
The company has raised significant funding from venture capital firms and public offerings, including a successful initial public offering in July 2020, raising $201.6 million.
Overall, Iteos Therapeutics is a promising biotechnology company that has made significant progress in developing innovative immuno-oncology therapies.
With a strong pipeline, collaborations, and ample funding, the company has the potential to make a significant impact in fighting cancer.
Company Address: 321 Arsenal St Watertown 2472 MA
Company Phone Number: 217 0162 Stock Exchange / Ticker: NASDAQ ITOS
|
1.44%